Tuesday, May 4, 2010
Sex and Hormonal contraceptives: higher risk of female sexual dysfunction
Women taking non-oral and oral hormonal contraceptives were at highest risk of Female Sexual Dysfunction (FSD), according to a study of female German medical students published today in The Journal of Sexual Medicine. Interestingly, women taking non-hormonal contraceptives were at lowest risk for FSD, more than women not using any contraceptive.
"Sexual problems can have a negative impact on both quality of life and emotional well-being, regardless of age," said researcher Dr. Lisa-Maria Wallwiener of the University of Heidelberg, Germany. "FSD is a very common disorder, with an estimated prevalence of about two in five women having at least one sexual dysfunction, and the most common complaint appearing to be low desire."
"The causes of FSD are multifunctional and in recent years the possible role of hormonal contraception has been discussed," said fellow researchers Drs. Christian and Markus Wallwiener, University of Tuebingen, Germany. "Women tend to be aware that sexual dysfunction is often influenced by various factors such as stress and relationships, but our study has shown it might also be influenced by exogenous hormone application."
1,086 women were included in the study (roughly 2.5% of the overall female medical student population in Germany), who completed questionnaires designed to identify problems with sexual function, as well as other lifestyle factors including desire for children, pregnancy and whether they were smokers. 87.4% had used contraceptives in the last 6 months, and 97.3% had been sexually active within the last four weeks.
To analyse the effect of contraception on sexual function, women using multiple forms of contraception or who had not been sexually active within the last four weeks were excluded, leaving 1046 participants. Of this figure, 32.4% were considered at risk for FSD: 5.8% at high risk for hypoactive sexual desire disorder, 1% for arousal disorder, 1.2% for decreased lubrication, 8.7% for orgasm disorder, 2.6% for satisfaction problems, and 1.1% for pain.
The participants were then divided into four subgroups of oral (hormonal) contraception (OC), non-oral hormonal contraception (NOHC), nonhormonal contraception (NHC), and no contraception (NC). The group at lowest risk for FSD (highest sexual function score) was NHC (31.0), followed by NC (29.5) and OC (28.3), with NOHC (27.4) at highest risk. For desire and arousal, both OC and NOHC groups were at highest risk.
The method of contraception and smoking status were significant factors for total sexual function scores, with smokers scoring higher than non-smokers. Other factors including age, prior pregnancy, desire for children, and partnership status were not significant. Women not in stable relationships (regardless of contraception use) had higher desire but lower orgasm scores.
"In future research it would be interesting to see if there is a difference between the dosage of estrogen and the various synthetic progestins used in hormonal contraceptives in terms of an impact on female sexual function," added study researcher Dr. Harald Seeger, also of University of Tuebingen, Germany. "We would also urge some caution in interpretation of our present results and would like to highlight that this type of study cannot demonstrate causality but rather association and there might exist a multitude of factors that have an impact on female sexual function."
"This is a very important research investigation", stated Dr. Irwin Goldstein, Editor-in-Chief of the Journal of Sexual Medicine. "There are hundreds of millions of women, in particular young women at the beginning of their sexual lives, who regularly use hormonal contraception for many years. The irony is that these women are provided a medication that enables freedom from reproductive worries but these same women are not provided information that there are significant adverse sexual effects that may ensue.
"Agents that interfere with the hormonal milieu of women may adversely affect their sexual lives"
Link: http://www.wiley.com/wiley-blackwell
Monday, August 3, 2009
Woman Contracts Gorilla HIV: Proof of Direct Connection between SIV and HIV /AIDS
A new strain of HIV has jumped from gorillas to humans.
So far, only one person, a 62-year-old French woman from Cameroon, has been reported to be infected with the virus.
It very closely resembles strains of Simian Immunodeficiency Virus (SIV) recently discovered in western gorillas in the wild.
"It would be surprising if there aren't many more" human cases, says David Robertson, a bioinformaticist at the University of Manchester, UK who analysed the virus's DNA along with colleagues in France.
"We don't think this is a direct gorilla-to-human transmission." It is more likely to be the result of eating 'Bush meat', plus transmission via sexual activity.
Drug hope
Until 2004, the infected woman lived in a suburb of Cameroon's capital city Yaoundé, where she didn't come into contact with apes or eat their meat, SIV's primary route to humans . This means that she probably acquired the infection from another human, likely through sexual contact.
AIDS
The woman hasn't yet shown any sign of a compromised immune system, the hallmark of AIDS but tests on laboratory-cultured human cells suggest that the virus can replicate in the same white blood cells as other strains of HIV. However, the new virus should be susceptible to anti-retroviral drugs that slow the growth of other strains of HIV, Robertson says.
SIV
Based on its genetic sequence, the virus appears most closely related to a number of SIV strains collected recently in gorilla faecal samples from forests in Cameroon. These viruses also resemble "group O" strains of HIV, which infect far fewer people than other strains of HIV, most of them in Cameroon.
Original source
The discovery of a gorilla virus in humans could suggest that some of these group O viruses came from gorillas, Robertson says, but it's also possible that the virus originated chimpanzees and was transmitted independently to gorillas and to humans.
"Until we do more sampling we're also guessing a little bit," Robertson concedes.